Toxicity remains the single biggest hurdle in getting ADCs to market, and drug developers are striving to develop safer antibody drug conjugates while keeping efficacy high. Although ADCs have come far, there are still more advancements to be made, highlighted by the blockbuster Enhertu and the recently approved Elahere, both containing Black Box Warnings.

Created for all key stakeholders in this conversation, from pathology and toxicology to translation, nonclinical and clinical development, the ADC Toxicity Summit was the first and only event dedicated to providing case-study-led presentations and interactive discussions, enabling attendees to hold all the information needed to maximize therapeutic windows, from discovery to early clinical.

From finding optimal in vivo and in vitro models, managing and mitigating toxicities in the clinic, to finding ideal ADC design and dosage regimes, the ADC Toxicity Summit armed attendees with all they needed to widen their therapeutic windows and get therapies to market faster.